Claims for Patent: 9,066,930

Summary for Patent: 9,066,930

Title:	Activin receptor-like kinase-1 compositions and methods of use
Abstract:	Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists.
Inventor(s):	Yan; Minhong (Foster City, CA), Zhang; Gu (Millbrae, CA)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	13/112,954
Patent Claims:	1. A method of inhibiting lymphangiogenesis comprising administering to a subject in need of inhibition of lymphangiogenesis an effective amount of an ALK-1 immunoadhesin, whereby the lymphangiogenesis is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2, and wherein the subject suffers from a tumor. 2. The method of claim 1, wherein the tumor is carcinoma, lymphoma, blastoma, sarcoma, or leukemia. 3. A method for treating a pathological condition associated with lymphangiogenesis in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the pathological condition associated with lymphangiogenesis is treated, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2, and whereby the pathological condition associated with lymphangiogenesis is a tumor. 4. A method of inhibiting tumoral lymphangiogenesis in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumoral lymphangiogenesis is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2. 5. A method of disrupting pericyte organization in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the pericyte organization is disrupted, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2, and wherein the subject suffers from a tumor. 6. A method of inhibiting tumor growth in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumor growth is inhibited, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2. 7. A method of treating a tumor in a subject comprising administering to the subject an effective amount of an ALK-1 immunoadhesin, whereby the tumor is treated, wherein the ALK-1 immunoadhesin comprises amino acid residues 22-352 of SEQ ID NO: 2. 8. The method of claim 7, wherein the tumor is carcinoma, lymphoma, blastoma, sarcoma, or leukemia. 9. The method of claim 7, further comprising administering to the subject an effective amount of an anti-angiogenesis agent. 10. The method of claim 9, wherein the anti-angiogenesis agent is an antagonist of vascular endothelial growth factor (VEGF). 11. The method of claim 10, wherein the antagonist of VEGF is an anti-VEGF antibody. 12. The method of claim 11, wherein the anti-VEGF antibody is bevacizumab.

Details for Patent 9,066,930

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-11-09